To further evaluated the clinical significance of miR-203 expression in chemotherapeutic resistance and patient prognosis of GBM, SNAI2 expression was detected in tissues from 35 cases of patients with primary GBM and 16 cases of patients with relapsed GBM by immunohistochemistry. This evidence concerns the gene SNAI2 and glioblastoma.